TARDBP and amyotrophic lateral sclerosis: Our results are indeed largely consistent with those from the Okano group (Yang et al., 2013; Fujimori et al., 2018) who also demonstrated that these ALS treatments failed to protect against ALS MN neurite regression, cytotoxicity, and FUS + or phosphorylated-TDP-43 + protein aggregates following extended culture maturation times (∼ 40–70 days).